FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
A significant proportion of LGSC express high FOLR1 levels supporting the development of clinical trials to investigate ADCs targeting FOLR1 as novel agents for treating this disease. In LGSC, high FOLR1 expression was associated with fewer MAPK pathway alterations, low PR expression, and p16 loss.
Authors
- Anna Cameron (ORCID: https://orcid.org/0000-0003-1255-5807)
- Hannah Kim (ORCID: https://orcid.org/0000-0001-7138-6623)
- Linda S. Cook (ORCID: https://orcid.org/0000-0001-8641-0710)
- Marta Llauradó Fernández (ORCID: https://orcid.org/0000-0002-9589-2456)
- Mark Carey (ORCID: https://orcid.org/0000-0002-0473-6993)
- Madison Bittner (ORCID: https://orcid.org/0000-0001-6530-4361)
- Amy Dawson (ORCID: https://orcid.org/0000-0002-5207-7988)
- Stéphanie Gaillard (ORCID: https://orcid.org/0000-0002-2174-3693)
- Chanel Ghesquiere (ORCID: https://orcid.org/0000-0001-7413-2346)
- Anna V. Tinker (ORCID: https://orcid.org/0000-0002-1190-7746)
- Nelson K.Y. Wong (ORCID: https://orcid.org/0000-0002-7003-6020)
- Annalyn Da-Anoy
- Martin Köbel (ORCID: https://orcid.org/0000-0002-6615-2037)
- Joshua Hoenisch (ORCID: https://orcid.org/0000-0002-9096-051X)
- J Schmid
- Y Leung
- Gurdial Dhillion
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Johns Hopkins University (US)
- Colorado School of Public Health (US)
- University of Northern British Columbia (CA)
- University of Calgary (CA)
- Johns Hopkins Medicine (US)
- Spinal Cord Injury BC (CA)
- Positive Living North (CA)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e74
- Citations
- 13
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 22.07